{"denoms":[{"counts":[{"groupId":"BG000","value":"450"},{"groupId":"BG001","value":"450"},{"groupId":"BG002","value":"453"},{"groupId":"BG003","value":"450"},{"groupId":"BG004","value":"1803"}],"units":"Participants"}],"groups":[{"description":"Study Drugs Arimidex (Anastrozole), Zometa (Zoledronate; zoledronic acid)\n\nanastrozole: 1 mg/d\n\nzoledronic acid: 4 mg q6m\n\ngoserelin: 3.6 mg goserelin subcutaneously every 28 days","id":"BG000","title":"AZ (Arimidex+Zoledronate)"},{"description":"Study Drugs Nolvadex (Tamoxifen), Zometa (Zoledronate; zoledronic acid)\n\ntamoxifen: 20 mg/d\n\nzoledronic acid: 4 mg q6m\n\ngoserelin: 3.6 mg goserelin subcutaneously every 28 days","id":"BG001","title":"TZ (Tamoxifen+Zoledronate)"},{"description":"Study Drug Arimidex (Anastrozole)\n\nanastrozole: 1 mg/d\n\ngoserelin: 3.6 mg goserelin subcutaneously every 28 days","id":"BG002","title":"AC (Arimidex Control)"},{"description":"Study Drug Nolvadex (Tamoxifen)\n\ntamoxifen: 20 mg/d\n\ngoserelin: 3.6 mg goserelin subcutaneously every 28 days","id":"BG003","title":"TC (Tamoxifen Control)"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"28","upperLimit":"56","value":"44"},{"groupId":"BG001","lowerLimit":"27","upperLimit":"54","value":"45"},{"groupId":"BG002","lowerLimit":"25","upperLimit":"58","value":"44"},{"groupId":"BG003","lowerLimit":"27","upperLimit":"56","value":"45"},{"groupId":"BG004","lowerLimit":"25","upperLimit":"58","value":"45"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"450"},{"groupId":"BG001","value":"450"},{"groupId":"BG002","value":"453"},{"groupId":"BG003","value":"450"},{"groupId":"BG004","value":"1803"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"343"},{"groupId":"BG001","value":"339"},{"groupId":"BG002","value":"352"},{"groupId":"BG003","value":"341"},{"groupId":"BG004","value":"1375"}],"title":"pT1"},{"measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"97"},{"groupId":"BG002","value":"93"},{"groupId":"BG003","value":"98"},{"groupId":"BG004","value":"386"}],"title":"pT2/pT3"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"42"}],"title":"Unknown"}]}],"description":"The pathologic T-stage (pT) describes the categories of tumor size: pT1: \\<2 cm, pT2: 2 to 5 cm, pT3: \\> 5 cm.","paramType":"COUNT_OF_PARTICIPANTS","title":"pT-stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"304"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"304"},{"groupId":"BG003","value":"305"},{"groupId":"BG004","value":"1211"}],"title":"Negative"},{"measurements":[{"groupId":"BG000","value":"137"},{"groupId":"BG001","value":"138"},{"groupId":"BG002","value":"141"},{"groupId":"BG003","value":"134"},{"groupId":"BG004","value":"550"}],"title":"Positive"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"42"}],"title":"Unknown"}]}],"description":"The pathologic N-stage (pN) describes the categories of affected lymph nodes: negative: no lymph node affected, positive: at least one lymph node affected.","paramType":"COUNT_OF_PARTICIPANTS","title":"pN-stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"341"},{"groupId":"BG001","value":"347"},{"groupId":"BG002","value":"347"},{"groupId":"BG003","value":"346"},{"groupId":"BG004","value":"1381"}],"title":"G1/G2"},{"measurements":[{"groupId":"BG000","value":"93"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"89"},{"groupId":"BG003","value":"85"},{"groupId":"BG004","value":"352"}],"title":"G3"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"28"}],"title":"GX"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"42"}],"title":"Unknown"}]}],"description":"The histologic grade describes to which extent the cancer cells and their arrangement look look like normal cells. Grade 1 (G1): well-differentiated, cells look more like normal breast tissue; Grade (G2): moderately differentiated; Grade (G3): poorly differentiated; GX: grade cannot be assessed.","paramType":"COUNT_OF_PARTICIPANTS","title":"Histologic grade","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"67"}],"title":"Negative"},{"measurements":[{"groupId":"BG000","value":"424"},{"groupId":"BG001","value":"416"},{"groupId":"BG002","value":"431"},{"groupId":"BG003","value":"423"},{"groupId":"BG004","value":"1694"}],"title":"Positive"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"42"}],"title":"Unknown"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Estrogen receptor status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"40"},{"groupId":"BG004","value":"143"}],"title":"Negative"},{"measurements":[{"groupId":"BG000","value":"405"},{"groupId":"BG001","value":"404"},{"groupId":"BG002","value":"409"},{"groupId":"BG003","value":"399"},{"groupId":"BG004","value":"1617"}],"title":"Positive"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"43"}],"title":"Unknown"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Progesterone receptor status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"386"},{"groupId":"BG001","value":"382"},{"groupId":"BG002","value":"389"},{"groupId":"BG003","value":"379"},{"groupId":"BG004","value":"1536"}],"title":"No"},{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"25"},{"groupId":"BG004","value":"97"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"41"},{"groupId":"BG003","value":"46"},{"groupId":"BG004","value":"170"}],"title":"Unknown"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Preoperative chemotherapy","unitOfMeasure":"Participants"}]}